Form 4: Roberto Mignone Reports Changes in Beneficial Ownership of Teva Pharmaceutical Industries Ltd.
SEC Form 4 Filing
Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd., reports the acquisition and disposal of ordinary shares and restricted share units.
Summary
- On June 15, 2024, Roberto Mignone reported changes in his beneficial ownership of Teva Pharmaceutical Industries Ltd. securities.
- He acquired 21,108 ordinary shares through the vesting of restricted share units.
- He also disposed of 21,108 ordinary shares.
- Following these transactions, Mignone directly owns 1,595,683 ordinary shares.
- Additionally, he may be deemed to beneficially own 1,500,000 ordinary shares held by Swiftcurrent Partners, L.P. and Swiftcurrent Offshore Master, Ltd., although he disclaims beneficial ownership except to the extent of his indirect pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in the pharmaceutical industry and publicly traded companies in general.
Stakeholder Impact
- The change in ownership may have a minor impact on shareholders, as insider transactions are often monitored for signals about the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted |
| 06/15/2024 | Date of earliest transaction; Restricted Share Units vested |
| 06/17/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.